Revisiting complete response in light chain amyloidosis-Reference-Cited by-同舟云学术

Revisiting complete response in light chain amyloidosis

Published:2019-11-26 Issue:5 Volume:34 Page:1472-1475
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Sidana Surbhi^ORCID,Dispenzieri Angela,Murray David L.,Go Ronald S.^ORCID,Buadi Francis K.,Lacy Martha Q.,Gonsalves Wilson I.,Dingli David,Warsame Rahma,Kourelis Taxiarchis,Muchtar Eli^ORCID,Hayman Suzanne R.,Kapoor Prashant,Kyle Robert A.,Leung Nelson^ORCID,Rajkumar S. Vincent,Gertz Morie A.,Kumar Shaji K.^ORCID

Funder

Amyloidosis Foundation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0664-9.pdf

Reference15 articles.

1. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

2. Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011;86:251–5.

3. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018;32:729–35.